FDA panel backs new epilepsy drug from GSK, Valeant

GlaxoSmithKline and Valeant got a solid endorsement for their new epilepsy drug Potiga (ezogabine) from the FDA's panel of experts, putting them on track to a likely approval. The experts unanimously agreed that the drug would benefit epilepsy patients whose meds couldn't stop seizures. And they agreed that careful monitoring would flag patients who experience an inability to urinate while taking the drug. Two of the experts abstained on the main safety issue, which is typically reversible once...

FDA staffers weighs risks, rewards of new epilepsy drug

Staffers at the FDA have red-flagged their concern about cases of urinary retention tracked in some patients taking Valeant Pharmaceutical's experimental new epilepsy medicine Potiga (ezogabine), which comes before an advisory panel on Wednesday. But the staff review also noted that the drug appears to be effective and most cases of an inability to urinate were reversible. Valeant is looking for an FDA approval to use the medicine as part of a combinational approach to...

Epilepsy Pipeline Update 2010 Showcasing New and Promising Epilepsy Therapies to Be Held in San Francisco

February 25-26 Forum to Bring Together Innovators, Clinicians and Investors MIDDLEBURG, Va., Jan. 12 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP), a non-profit organization dedicated to advancing new therapies for people living with epilepsy, announces the Epilepsy Pipeline Update...

Diet rich in omega-3 fatty acids linked to improved nervous-system function

The omega-3 essential fatty acids commonly found in fatty fish and algae help animals avoid sensory overload, according to research published by the American Psychological...